NKGen Biotech to Present New SNK01 Clinical Trial Data at 2024 Alzheimer's Conference

On July 18, 2024, NKGen Biotech, Inc. (Nasdaq: NKGN) announced that it would present new biomarker data on its SNK01 therapy for Alzheimer’s disease at the Alzheimer’s Association International Conference (AAIC), scheduled to take place in Philadelphia, PA, and online from July 28 to August 1, 2024. NKGen Biotech is a clinical-stage biotechnology company focused on developing and commercializing innovative natural killer (NK) cell therapeutics, including autologous, allogeneic, and CAR-NK cell therapies.

The company will present data highlighting SNK01’s efficacy in reducing α-synuclein levels in Alzheimer’s patients. This reduction is crucial because increased levels of α-synuclein have been linked to worsening cognitive function in Alzheimer’s disease. The presentation, titled "Subjects treated with expanded non-genetically modified autologous Natural Killer cells (SNK01) show improved changes in CSF α-synuclein and in cognitive function," will be delivered by Dr. Paul Y. Song.

The company has previously disclosed Phase 1 data demonstrating SNK01’s positive effects on amyloid, tau, and neuroinflammation biomarkers in Alzheimer's patients. These earlier findings, which may not be included in the upcoming poster presentation, are also accessible on the Scientific Publications webpage.

NKGen Biotech, headquartered in Santa Ana, California, is committed to advancing the field of NK cell therapeutics. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!